Ann Oncol. 2007 May;18(5):827-34, Yan TD, Welch L, Black D, Sugarbaker PH.
In the past, peritoneal mesothelioma was regarded as a preterminal condition. The length of survival was dependent upon whether the cancer itself was aggressive or slow. The median survival was approximately 1 year after chemotherapy.
Surgery combined with intraperitoneal chemotherapy has been used as a treatment alternative, but the efficacy of this combined treatment remains to be established.
Seven prospective observational studies from six tertiary institutions were available, allowing 240 peritoneal mesothelioma patients for assessment. The median survival ranged from 34-92 months. The 1-, 3- and 5-year survival varied from 60% to 88%, 43% to 65% and 29% to 59%, respectively. This systematic review demonstrated an improved overall survival, as compared to historical controls, using systemic chemotherapy and palliative surgery.
Information about mesothelioma medical and legal options provided by the Law Office of Roger G. Worthington, P.C., www.mesothel.com.